Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pyrotinib Combined With Trastuzumab and Albumin Paclitaxel in First-line Treatment of HER2-positive Advanced or Metastatic Breast Cancer, a Prospective, Single-arm, Multicenter, Phase II Study

NCT05429294 is registered in ClinicalTrials.gov with First Affiliated Hospital Xi'an Jiaotong University as lead sponsor.

NCT NCT05429294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05429294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pyrotinib Combined With Trastuzumab and Albumin Paclitaxel in First-line Treatment of HER2-positive Advanced or Metastatic Breast Cancer, a Prospective, Single-arm, Multicenter, Phase II Study
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2022
Completion date
October 30, 2024
Enrollment
209 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

her2-positive breast cancer